LEXINGTON, Mass.--(BUSINESS WIRE)--NitroMed, Inc. (NASDAQ:NTMD) announced that Michael L. Sabolinski, M.D. will resign as chief medical officer of the Company, effective at the end of the month. After fourteen months in this role and four years with the company, Dr. Sabolinski is leaving to become a partner at FOXKISER a public health policy, regulatory and drug development firm.
